問卷

TPIDB > Search Result

Search Result

篩選

List

137Cases

2017-01-15 - 2020-01-31

Phase I

Completed
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, IlarisR (canakinumab) or MekinistR (trametinib)
  • Condition/Disease

    Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

  • Test Drug

    PDR001、CJM112、ACZ885/Ilaris® 、EGF816、TMT212/Mekinist®

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

2018-04-02 - 2023-12-06

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2007-11-14 - 2009-12-29

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2019-03-18 - 2024-12-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2008-06-01 - 2012-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-10-15 - 2011-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-08-01 - 2012-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-09-01 - 2027-05-01

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2016-06-07 - 2020-03-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Terminated4Sites